Trial Profile

Phase I Study of TAS-120 in Patients with Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Futibatinib (Primary)
Indications Cholangiocarcinoma; Solid tumours
Focus Adverse reactions
Sponsors Taiho Pharmaceutical

Most Recent Events

06 Mar 2023 New trial record
21 Jan 2023 Results of pooled retrospective analysis( As of October 1, 2020, n=318 from two studies NCT02052778/JapicCTI-142552) assessing futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers presented at the 2023 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com